Medicine and Dentistry
Brain Metastasis
100%
Surgery
95%
Diseases
91%
Melanoma
88%
Ganglioglioma
67%
Glioblastoma
62%
Overall Survival
59%
Neoplasm
59%
Functional Magnetic Resonance Imaging
49%
Metastatic Carcinoma
44%
Intracranial Tumor
36%
Stereotactic Radiosurgery
36%
Malignant Neoplasm
31%
Immunotherapy
31%
Immunity
28%
Clinical Trial
25%
STAT3 Protein
22%
Magnetic Resonance Imaging
21%
Nivolumab
21%
Metastatic Melanoma
20%
Diagnosis
19%
Tumor Microenvironment
18%
DNA Template
18%
Xenograft
16%
T Cell
15%
Medicine
14%
Radiation Therapy
14%
Mesenchymal Stem Cell
14%
Central Nervous System Metastasis
14%
Ventricle of Heart
14%
Immunosuppressive Treatment
13%
Progression Free Survival
13%
Recurrent Disease
12%
Tumor Progression
12%
Cumulative Incidence
10%
Radiation Necrosis
10%
Molecular Pathology
9%
Macrophage
9%
Oligoastrocytoma
9%
Radiology
8%
Therapy Effect
8%
Hope
8%
Primary Tumor
8%
Survival Time
8%
Clinical Study
8%
Meta-Analysis
8%
Multivariate Analysis
8%
Combination Therapy
8%
Cancer
7%
Patient Population
7%
Keyphrases
Leptomeningeal Disease
64%
Glioblastoma
52%
Brain Metastases
50%
Glioma
42%
Overall Survival
35%
Melanoma Brain Metastases
28%
Melanoma
28%
Tumor
25%
Radiotherapy
22%
CNS Metastases
22%
Nivolumab
21%
Phase 1 Trial
21%
Disease Stage
21%
Intrathecal
21%
Glioblastoma multiforme
21%
Metastatic Melanoma
18%
Melanoma Patients
18%
MD Anderson Cancer Center
17%
University of Texas
17%
Malignant Glioma
17%
Tumor Microenvironment
16%
Gross Total Resection
16%
Resection
16%
Signal Transducer and Activator of Transcription 3
14%
Primary Brain Tumor
14%
Improved Outcomes
14%
Convection-enhanced Delivery
14%
Surgical Management
14%
Houston
14%
Stereotactic Radiosurgery
14%
Pre-surgical
14%
Clinical Trials
13%
Poor Prognosis
13%
Brain Tumor
12%
Operative
11%
Tumor Progression
11%
Long-term Survival
11%
Therapeutic Effect
11%
Magnetic Resonance Imaging
11%
Treatment Options
10%
Ependymoma
10%
Immune Parameters
10%
Tumor Volume
10%
Clinical Features
10%
Median Overall Survival
10%
Single Institution
9%
San Francisco
9%
Pathology Department
9%
Molecular Pathology
9%
Treatment Modalities
9%